Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile

Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological Profile

0 Ungluers have Faved this Work
For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile.

This book is included in DOAB.

Why read this book? Have your say.

You must be logged in to comment.

Rights Information

Are you the author or publisher of this work? If so, you can claim it as yours by registering as an rights holder.


This work has been downloaded 20 times via ebook links.
  1. 3 - pdf (CC BY-NC-ND) at


  • 1-methylcytosine
  • ?0
  • ?–? stacking
  • amidophosphine
  • Angiogenesis
  • anticancer
  • anticancer agents
  • anticancer drug
  • antimigration
  • antiproliferative
  • antiproliferative activity
  • aquaporins
  • biomacromolecules
  • Bones
  • Cancer
  • chromatographic lipophilicity parameter
  • copper and iron chelators in cancer
  • cyclodextrin
  • Cytotoxicity
  • Dendrimers
  • distribution coefficient
  • DNA cleavage
  • DNA interaction
  • Drug Discovery
  • Encapsulation
  • fluorescence quenching
  • Gold
  • gold fingers
  • Gold(III) complexes
  • HPLC
  • HSA binding
  • HSA oxidation
  • imaging
  • isatin-derived ligands
  • lipophilicity
  • liposomes
  • Log kw
  • Log P
  • metal complex
  • metallodrugs
  • metallomics
  • metastasis
  • micelles
  • MRI
  • n/a
  • Nanoparticles
  • Nanotubes
  • oxindolimine–metal complexes
  • partition coefficient
  • pet
  • phosphonates
  • photoactivation
  • Platinum
  • platinum iodido complexes
  • platinum(IV)
  • protein-DNA recognition
  • pyridine benzimidazole
  • ruthenium
  • ruthenium complexes
  • Silver
  • stopped-flow spectroscopy
  • targeting
  • thiophene
  • transmetalation
  • upconverting nanoparticles
  • zinc finger proteins


DOI: 10.3390/books978-3-03921-316-0


edition cover
edition cover


Copy/paste this into your site: